Ash 2024 Annual Meeting – Presented encouraging preliminary Phase 1 data at the ASH Annual Meeting, which demonstrated clinically meaningful development that will be recognized as collaboration revenue in 2024. Total . The neuroscience space saw a late push in merger and acquisition activity, while oncology start-ups reeled in the most venture capital funds. Industry leaders expect these trends to continue. .
Ash 2024 Annual Meeting
BRC at ASH 2022 | UNC Blood Research Center
65th ASH Annual Meeting & Exposition Hematology.org
66TH ASH ANNUAL MEETING & EXPOSITION 2024
Registration Information Hematology.org
ASH on X: “From broken attendance recordings to revolutionary
Aviva Wolff, EdD, OT, CHT on LinkedIn: We want to hear from you
Brocha Stern on X: “Looking forward to seeing your practice
Summary 11th Annual ASH Highlights
Highlights of ASH in North America Hematology.org
Ash 2024 Annual Meeting 65th ASH Annual Meeting & Exposition Hematology.org: Arcellx, Inc. (NASDAQ: ACLX) posted financial results for its fourth quarter on Wednesday. The company posted net income of $20.5 million for the quarter ended Dec. 31, 2023, compared to a year-ago . Feb. 26, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences data from the Phase 2 SUMMIT and APEX trials at the American Society of Hematology (ASH) annual meeting. Highlights from APEX, a .
]]>